World Journal of Pharmaceutical Sciences

ANALYTICAL METHOD DEVELOPMENT AND RAPID ANALYTICAL TECHNIC FOR SIMULTANEOUS ESTIMATION OF MONTELUKAST AND BILASTINE IN BULK AND PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC METHOD

2025-10-17T12:47:20+00:00

A simple, Accurate, precise method was developed for the simultaneous estimation of the Bilastine and Montelukast in bulk and pharmaceutical dosage form. Chromatogram was run through Agilent C18 150 x 4.6 mm, 5mm. Mobile phase containing Buffer :Acetonitrile taken in the ratio 70:30 was pumped through column at a flow rate of 1.0 ml/min. Buffer used in this method was 0.01N Na2Hpo4 buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 265.0 nm. Retention time of Bilastine and Montelukast were found to be 2.141 min and 2.605 min. %RSD of the Bilastine and Montelukast were and found to be 0.4% and 0.2% respectively. %Recovery was obtained as 99.47% and 99.55% for Bilastine and Montelukast respectively. LOD, LOQ values obtained from regression equations of Bilastine and Montelukast were 0.1, 0.03 and 0.03, 0.10 respectively. % Assay was obtained as 99.74% and 99.72% for Bilastine and Montelukast respectively. Regression equation of is Montelukast y = 45726x + 6306.9, y = 43360x + 810 of Bilastine.

RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF TENEGLIPTIN AND REMOGLIFLOZIN IN BULK AND PHARMACEUTICAL DOSAGE FORM

2025-10-17T12:57:58+00:00

Simultaneous estimation of the Remogliflozin and Teneligliptin in pharmaceutical dosage form. Chromatogram was run through Discovery C18 250 x 4.6 mm, 5m. Mobile phase containing Buffer Ammonium acetate: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 0.9 ml/min.. Temperature was maintained at 30°C. Optimized wavelength selected was 229 nm. Remogliflozin and Teneligliptin were eluted at 2.139 min and 2.176 min respectively. %RSD of the Remogliflozin and Teneligliptin were and found to be 0.6 and 0.7 respectively. %Recovery was obtained as 99.50% and 99.50% for Remogliflozin and Teneligliptin respectively. LOD, LOQ values obtained from regression equations of Remogliflozin and Teneligliptin were 0.11, 0.33 and 0.005, 0.014 respectively. Regression equation of Remogliflozin is y = 52813x + 14718, and y = 69817x + 586.95 of Teneligliptin.

HPLC-BASED METHOD DEVELOPMENT AND VALIDATION FOR QUANTIFICATION OF NIRMATRELVIR AND RITONAVIR IN COMBINATION THERAPY

2025-10-17T12:54:25+00:00

A simple, Accurate, precise method was developed for the simultaneous estimation of the Nirmatrelvir and Ritonavir in pharmaceutical dosage form. Chromatogram was run through Kromasil C18 250 x 4.6 mm, 5. Mobile phase containing Buffer 0.1% OPA : Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 1.0ml/min. Buffer used in this method was 0.1% OPA. Temperature was maintained at 30°C. Optimized wavelength selected was 240 nm. Nirmatrelvir and Ritonavir were eluted at 2.303 min and 2.783 min respectively. %RSD of the Nirmatrelvir and Ritonavir were and found to be 0.8 and 0.5 respectively. %Recovery was obtained as 99.63% and 99.70% for Nirmatrelvir and Ritonavir respectively. LOD, LOQ values obtained from regression equations of Nirmatrelvir and Ritonavir were 0.04, 0.13 and 0.01, 0.02 respectively. Regression equation of Nirmatrelvir is y = 92901x + 3504.3, and y = 116867x + 4632.7 of Ritonavir.

RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF PREGABALIN AND ETORICOXIB IN PHARMACEUTICAL FORMULATIONS

2025-10-17T12:56:17+00:00

The simultaneous estimation of the Pregabalin and Etoricoxib in Tablet dosage form. Chromatogram was run through Agilent C18 150 mm (4.6 x 150mm, 5μm) Mobile phase containing Buffer 70% (Ammonium acetate ) :40% Acetonitrile was pumped through column at a flow rate of 1 ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 234.0 nm. Retention time of Pregabalin and Etoricoxib were found to be 2.233 min and 2.712 min. %RSD of the Pregabalin and Etoricoxib were and found to be 0.5 and 0.5 respectively. %Recovery was obtained as 100.06% and 99.81% for Pregabalin and Etoricoxib respectively. LOD, LOQ values obtained from regression equations of Pregabalin and Etoricoxib were 0.03, 0.09 and 0.02, 0.06 respectively. Regression equation of Pregabalin is y = 33728x + 2248.7, and y = 37618x + 3978.9 of Etoricoxib.